Home > Insider Trading > Filing (0001209191-15-003774)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1305253	Celladon Corp	CLDN	Biological Products, (No Disgnostic Substances) (2836)	330971591

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1590705	J Jeffrey Rudy	11988 El Camino Real, Suite 650 San Diego CA 92130	Vp, Clinical Operations	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2015-01-09	10,000	$1.12	11,024	No	4	M	Direct
Common Stock	Disposition	2015-01-09	10,000	$18.51	1,024	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock option (right to buy)	Disposition	2015-01-09	10,000	$0.00	10,000	$1.12

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
181,738	2013-01-27	2022-06-14	No	4	M	Direct

Footnotes

The amount includes shares purchased under Celladon Corporation's employee stock purchase plan prior to the reported transaction.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the reporting person.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.82 per share, inclusive. The reporting person undertakes to provide to Celladon Corporation, any security holder of Celladon Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
25% of the shares subject to the option vested and became exercisable on the one year anniversary of January 27, 2012 (the "Vesting Commencement Date"), and 1/48th of the shares vest in equal monthly installments thereafter, over the remaining three years.